Unmasking Advances in Oncology 44th Annual JP Morgan Healthcare Conference Dr. Sean McCarthy, CEO and Chairman January 14, 2026 © 2026 CytomX Therapeutics, Inc. 1 Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events, including those related to varsetatug masetecan and CX-801. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, techno ...

Core Viewpoint - Oncolytics Biotech Inc. has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics to enhance its operational, clinical, and regulatory capabilities as it advances registration-directed development programs in gastrointestinal cancers [1][4]. Group 1: Appointments and Roles - John McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio, bringing extensive experience in leading late-stage oncology programs [2][3]. - Yujun Wu will lead Biostatistics, contributing expertise in statistical strategy, regulatory interactions, and late-stage trial design, having previously supported multiple clinical programs through late-stage development [3][4]. Group 2: Strategic Focus - The appointments support Oncolytics' strategic focus on advancing pelareorep through efficient regulatory pathways, prioritizing indications with high unmet medical need, including squamous cell anal cancer, pancreatic cancer, and KRAS-mutant colorectal cancer [4][10]. - The Company is actively pursuing accelerated approval strategies and pivotal trials, emphasizing the importance of high-quality statistical leadership at this critical time [4][10]. Group 3: Inducement Awards - In connection with their appointments, the Company granted inducement equity awards to Mr. McAdory and Mr. Wu, including stock options with an exercise price of US$0.97 [5][6]. - Mr. McAdory received an award of 300,000 restricted share units that will vest upon a material transaction, while he also received 500,000 stock options [7][8].

Core Viewpoint - ImmunityBio, Inc. has received accelerated approval from the Saudi Food and Drug Authority for ANKTIVA® in combination with immune checkpoint inhibitors for treating adult patients with metastatic non-small cell lung cancer who have progressed after standard therapy [1] Group 1 - The approval of ANKTIVA® represents a significant milestone as it is the first approval of this treatment in the region [1] - The indication is specifically for adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy [1]

Core Viewpoint - ImmunityBio, Inc. has received approval from the Saudi Food and Drug Authority for ANKTIVA® in combination with Bacillus Calmette-Guérin (BCG) for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ [1] Regulatory Approval - The approval by the SFDA expands the existing approvals for ANKTIVA® in the United States [1]

Oncolytics Biotech PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors January 2026 Forward-Looking Statements Oncolytics Biotech Confidential This presentation is strictly confidential. Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any representation to the contrary is a criminal offense. This presentation does not constitute an offer to sel ...

Core Viewpoint - Evaxion A/S is expanding its AI-Immunology™ platform to include the discovery and development of treatments for autoimmune diseases, alongside its existing focus on cancers and infectious diseases, aiming to address high unmet medical needs and enhance partnership opportunities [1][7]. Group 1: Expansion of AI-Immunology™ Platform - The expansion will leverage the scalability of the AI-Immunology™ platform, increasing the range of diseases that can be targeted for new treatments [2]. - Autoimmune diseases are characterized by significant unmet medical needs, presenting substantial partnership potential throughout all stages of drug development [2][7]. Group 2: Strategic Milestones for 2026 - The company has outlined several milestones for 2026, including the introduction of the AI-Immunology™ application for autoimmune diseases in the second half of the year [5][6]. - Other milestones include additional biomarker and immunogenicity data for EVX-01, three-year phase 2 clinical efficacy data for EVX-01, regulatory filing for phase 1 trial of EVX-04, and design and preclinical validation of antigens for EVX-B4, all targeted for the second half of 2026 [6]. Group 3: Financial Outlook - The development of applications for autoimmune diseases is included in Evaxion's cash flow outlook and will not affect its cash runway, which extends into the second half of 2027 [4].

Core Insights - BriaCell Therapeutics Corp. announced the complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, a personalized off-the-shelf immunotherapy [1][2][6] Group 1: Patient Outcomes - The first patient in the Bria-OTS study, a 78-year-old woman with advanced MBC, achieved a 100% resolution of a lung metastasis after four doses of Bria-OTS therapy [2] - The complete response was confirmed at multiple intervals: 2 months, 4 months, 6 months, and now at 11 months [2][3] - The patient received a total of 17 cycles of Bria-OTS and completed 12 months of the study, remaining in survival follow-up [2] Group 2: Study Progress - The Phase 1 dose escalation portion of the Bria-OTS study is complete, and the Phase 2a portion, which evaluates the combination of Bria-OTS with an immune checkpoint inhibitor, is currently underway [5][9] - The clinical findings from the study have reinforced confidence in the therapeutic potential and safety of the Bria-OTS platform [6] Group 3: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [10]

Transformative immunomodulating medicines for patients January 2026 To add/change the picture: • Click on the image and press BACKSPACE or DELETE on the keyboard > Click on the icon at the centre of the placeholder > Select the chosen image • To adjust the crop, right-click on the image > Crop • If for any reason the image placeholder loses the rounded shape, click on Reset button in the Home tab at the top. To add/change the picture: • Click on the image and press BACKSPACE or DELETE on the keyboard > Clic ...

Core Insights - Dispatch Bio and CARsgen Therapeutics announced a clinical collaboration to conduct a Phase 1 trial in China, set to begin in 2026, focusing on solid tumors [1][2] Company Overview - Dispatch Bio is engineering a universal treatment for solid tumors using its Flare platform, which combines immunotherapy with a tumor-specific virus [7] - CARsgen Therapeutics specializes in developing innovative CAR T-cell therapies, addressing unmet clinical needs in hematologic malignancies and solid tumors [8] Clinical Trial Details - The trial will evaluate DISP-11, which utilizes Dispatch's Flare platform and CARsgen's zevorcabtagene autoleucel (zevor-cel), targeting patients with solid tumors [2][3] - Zevor-cel is an autologous BCMA-targeting CAR T-cell therapy approved in China for multiple myeloma [2][6] Strategic Collaboration - The collaboration aims to enhance the application of CAR T technologies for solid tumors, particularly those lacking specific targets [3] - This partnership is seen as a significant step in addressing the unmet medical needs in oncology and expanding the impact of the Flare platform [4] Technological Innovation - Dispatch's Flare platform addresses challenges in solid tumors by delivering a tumor-specific virus that creates a universal synthetic antigen, enhancing T cell recognition and reshaping the tumor microenvironment [5] - Preclinical findings presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting support the safety and therapeutic promise of the Flare platform [5]

Core Viewpoint - OSR Holdings, Inc. announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG for a global exclusive licensing transaction for VXM01, Vaximm's lead immunotherapy candidate [1][2] Group 1: Licensing Agreement Details - BCM Europe intends to establish a dedicated investment vehicle, BCM Decentralized Science Investors I, LP, which will act as the Licensee under the proposed licensing agreement [2] - The agreement includes an upfront payment of $30 million, structured as 50% cash and 50% digital assets, and aggregate milestone payments of up to $815 million, primarily focused on clinical and development achievements [7] - A royalty pass-through structure will allow the Fund to pass through royalty revenues from a future sublicensee or commercial partner to Vaximm, with a reconciliation mechanism for milestone payments [7] Group 2: Clinical and Market Potential - VXM01 has shown encouraging clinical and safety data across multiple indications, indicating its potential value as a differentiated immunotherapy asset [3] - The binding term sheet reflects third-party confidence in VXM01's value and the intent of BCM Europe to close the deal [4] - If the licensing agreement is completed, it would provide a strong foundation for advancing VXM01 into later-stage development while preserving long-term upside for Vaximm [3] Group 3: Company Background - OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in healthcare and wellness, engaging in immuno-oncology, regenerative biologics, and medical device technologies [5] - Vaximm AG is a privately held Swiss-German biotechnology company that utilizes a proprietary orally administered T-cell vaccination platform to induce robust cellular immune responses [6] - BCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings [8]